Sign in
WithdrawnPhase 2

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

Key facts

Who runs it
Stanford University
Where
Stanford, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Starts
1 Dec 2030
Expected to end
Dec 2030
Type of study
Interventional
Treatments tested
  • Ivermectin Pill
Record updated
2 December 2024
Why it stopped
Limited clinical capacity

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Must have at least one lesion of atopic dermatitis (At least 1% Body surface Area)
  • 18 years of age or older
  • Must be willing to take oral ivermectin once weekly for 4 weeks and monitor over 8 weeks
  • For women of child bearing potential, a negative urine pregnancy test
  • Women of child bearing potential are expected to use an effective method of birth control while participating in the study and for 1 month after taking the last dose
  • For male subjects with female partners of childbearing potential, agreement to use adequate contraception while participating in the study and for 1 month after taking the last dose
  • Has signed and dated the current Institutional Review Board approved informed consent document
  • Must be able to read and speak English fluently

Who cannot take part

  • Has had known or previous hypersensitivity or allergic reactions to oral ivermectin before
  • Taking any medication known to interact with ivermectin like Dasabuvir (theoretical) or warfarin (probable)
  • Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results
  • Has a history of hypersensitivity to any substance in investigational preparation
  • Has other skin conditions that might interfere with Atopic Dermatitis diagnosis and/or evaluation (i.e. psoriasis current active viral, bacterial and fungal skin infections) as assessed by the Investigator
  • Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation
  • History of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction
  • History of current evidence of malabsorption or liver disease
  • Has any clinically significant medical condition or laboratory abnormality that would, in the opinion of the Investigator, put the patient at undue risk or interfere with the interpretation of the study results
  • Is age <18 years old
  • Is currently participating or has participated in another interventional clinical study in the past 2 weeks
  • Is planning a trip to a sunny climate, to use tanning booths or use other UV sources throughout the course of this study
  • Is currently pregnant or breastfeeding
  • Cannot read and speak English fluently
  • Does not have at least 1% body surface area with lesional atopic dermatitis

Where in United States

  • Stanford Hospital and ClinicsStanford, United States

About the trial

What the trial wants to find out

This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.

The group in the trial

  • Oral treatmentTreatment being tested

    12mg oral ivermectin treatment taken once a week for four weeks

    Treatment: Ivermectin Pill

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
2 December 2024